Nakanishi et al. suggested that since smoking plays a key role in the pathophysiology of atherosclerosis and metabolic syndrome, both of which are associated with elevated FGF21 levels, it may influence plasma FGF21 levels by contributing to progression of these conditions (14). The gene discussed is FGF21; the disease is metabolic syndrome.